Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,597,876

« Back to Dashboard
Patent 8,597,876 protects PREZISTA and PREZCOBIX and is included in three NDAs. There has been one Paragraph IV challenge on Prezista. There are three tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

Protection for PREZISTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 8,597,876

Title:Method of treating HIV infection
Abstract: Disclosed is a method of treating human immunodeficiency virus (HIV) infection in an antiretroviral treatment-experienced mammal, which involves administering to the mammal an effective amount of a compound of the formula: ##STR00001## or a pharmaceutically acceptable salt, a prodrug, or an ester thereof, or a pharmaceutically acceptable composition of the compound, the salt, the prodrug, or the ester thereof, wherein A, X, Q, W, m, and R.sup.2-R.sup.6 are as defined herein.
Inventor(s): Erickson; John W. (Frederick, MD), Gulnik; Sergei V. (Frederick, MD), Mitsuya; Hiroaki (Chevy Chase, MD), Ghosh; Arun K. (West Lafayette, IN)
Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services (Washington, DC) N/A (Urbana, IL) Board of Trustees of the University of Illinois (
Application Number:11/870,931
Patent Claim Types:
see list of patent claims
Use; Composition;
Patent Metrics:
Source: PatentQuant.com
Field: Biotechnology
Back Citations: 0th percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Janssen Prods
darunavir ethanolate
TABLET;ORAL021976-004Dec 18, 2008RXNo8,597,876*PEDDec 23, 2019Y
Janssen Prods
darunavir ethanolate
TABLET;ORAL021976-005Dec 18, 2008RXNo8,597,876*PEDDec 23, 2019Y
Janssen Prods
darunavir ethanolate
TABLET;ORAL021976-001Jun 23, 2006DISCNNo8,597,876*PEDDec 23, 2019Y
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.